"rationale","name","instanceType","uuid:ID","id","description","label"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1","StudyDesign","4df7f6d5-2d00-4d94-ad96-fdd51ebb9023","StudyDesign_1","The main design for the study",""
